News

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted…
Read More...

Merck, known as MSD outside the United States and Canada, and Eisai announced that the U.S. Food and Drug Administration (FDA) approved the combination of KEYTRUDA, Merck’s anti-PD-1…
Read More...

AlivaMab Discovery Services, a company providing custom human therapeutic antibody drug discovery services using the AlivaMab Mouse, a best-in-class antibody discovery platform,…
Read More...

Accenture has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes. The platform, which…
Read More...

Alnylam Pharmaceuticals announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi…
Read More...

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems,…
Read More...

H. Lundbeck A/S (Lundbeck) and Alder BioPharmaceuticals announced a definitive agreement for Lundbeck to acquire Alder. Under the terms of the agreement, Lundbeck will commence a tender…
Read More...

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of…
Read More...

Oncoheroes Biosciences Inc and Boehringer Ingelheim International GmbH have signed a worldwide, exclusive licensing agreement for volasertib, an investigational anti-cancer compound…
Read More...

Akari Therapeutics, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme)…
Read More...

Castle Creek Pharmaceutical Holdings, Inc. announced it has reached an agreement to acquire Fibrocell Science, a cell and gene therapy company focused on transformational autologous…
Read More...

Vertex Pharmaceuticals Incorporated announced that eligible cystic fibrosis patients living in Scotland will now have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI…
Read More...

GlaxoSmithKline announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe…
Read More...

Sharp – part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has received Investigational Medicinal Product (IMP) and Wholesale Distribution…
Read More...

Aytu BioScience, a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, a specialty…
Read More...

Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, announced it has formed a strategic alliance with…
Read More...

Hansoh Pharmaceutical Group Company Limited and Atomwise have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in…
Read More...

Avalon Ventures announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. Sitari has been developing a novel…
Read More...

Mallinckrodt plc, a global biopharmaceutical company, today announced it has entered into a definitive agreement to sell its wholly owned subsidiary BioVectra Inc. to an affiliate of…
Read More...